Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ACP-204

Phase 3Small molecule

AACADIA Pharmaceuticals Inc.

2

Indications

4

Total Trials

4

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's Disease PsychosisEnrolling by invitation

Lewy Body Dementia PsychosisEnrolling by invitation

Alzheimer's Disease PsychosisPhase 3

Enrolling by invitation

Lewy Body Dementia PsychosisPhase 3

Enrolling by invitation

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Alzheimer's Disease Psychosis

NCT06159673

Phase 2Recruiting

Lewy Body Dementia Psychosis

NCT07029581

Clinical

Trials by Indication[1]

Alzheimer's Disease Psychosis2 trials

A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis

Recruiting·AACADIA Pharmaceuticals Inc.·Preclinical·NCT06159673·1,074 enrolled

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis

Enrolling by invitation·AACADIA Pharmaceuticals Inc.·Phase 3·NCT06194799·752 enrolled

Lewy Body Dementia Psychosis2 trials

A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Recruiting·AACADIA Pharmaceuticals Inc.·Phase 2·NCT07029581·180 enrolled

52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Enrolling by invitation·AACADIA Pharmaceuticals Inc.·Phase 3·NCT07095465·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ACP-204. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACP-204 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACP-204. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ACADIA Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AACADIA Pharmaceuticals Inc.

Related News